mRNA Biodistribution

Creative Bioarray offers the RNA ISH assay to visualize and monitor the delivery and biodistribution of these synthetic mRNA molecules to access the specificity and efficacy of these therapies. Our mRNA Biodistribution services can help you validate and accelerate your gene therapy development. We have supported dozens of gene therapy companies for research studies enabling pre-IND submission.

RNA ISH assay is an advanced in situ hybridization assay that allows for the visualization of single-molecule gene expression directly in intact tissues with single cell resolution. The assay represents a major advancement in RNA ISH approaches with its proprietary probe design to amplify target-specific signals but not background noise from non-specific hybridization. RNA ISH assay can help optimize the design and delivery methods of siRNA gene therapy, ensuring effective and targeted delivery of therapeutic siRNA molecules.

Figure 1. RNA FISH analysis of Syrian hamsters vaccinated with Flu-RBD. (A) Evaluation of local distribution of SARS-N in lung tissues of hamsters. SARS-N (red), pan-cytokeratin (greeen). Scale bar, 50 μm. (B) RNA FISH images revealing regional distribution and levels of viral RNA in lung tissues. Scale bar, 100 μm. Representative images of MPO.

Messenger RNA (mRNA) has merged as a new category of therapeutic agent to prevent and treat various diseases. To function in vivo, mRNA requires safe, effective and stable delivery systems that protect the nucleic acid from degradation and that allow cellular uptake and mRNA release. However, developing mRNA therapeutics remains challenging as they often have unintended off-target effects and cause non-specific toxicity. Additionally, the main hurdle for the application to a broader range of disorders is delivery to target tissues.

Detection of mRNAs requires a robust, highly specific, and highly sensitive assay with minimal time, ease of effort, and ease of data interpretation. While microarrays and PCR both provide useful molecular profiles of diseases, important clinically relevant cell and tissue context information is lost along with the spatial variation of gene expression patterns. The RNA ISH Assay is an advanced in situ hybridization assay leveraging the RNA ISH asasy core technology that allows for the visualization of small RNA expression in intact tissues or cultured cells with single-cell resolution.

mRNA Biodistribution Tests Available:

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for choosing Creative Bioarray as your preferred mRNA Biodistribution Service provider.

References

1. Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).
2. Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
3. Hajj, K. A. & Whitehead, K. A. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2, 17056 (2017).
4. Xiong, Q., Lee, G. Y., Ding, J., Li, W. & Shi, J. Biomedical applications of mRNA nanomedicine. Nano Res. 11, 5281–5309 (2018).
5. Li, B., Zhang, X. & Dong, Y. Nanoscale platforms for messenger RNA delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11, e1530 (2019).
6. Meng, C., Chen, Z., Li, G., Welte, T. & Shen, H. Nanoplatforms for mRNA therapeutics. Adv. Ther. 4, 2000099 (2021).
7. Kim, J., Eygeris, Y., Gupta, M. & Sahay, G. Self-assembled mRNA vaccines. Adv. Drug Deliv. Rev. 170, 83–112 (2021).
8. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
9. Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 383, 2427–2438 (2020).